The researchers in the University of Helsinki and Helsinki University Hospital have studied in detail the intestinal microbiota of 14 patients treated with a fecal microbiota transplant. The patients suffered from recurrent Clostridium difficile infection, also known as antibiotic-associated diarrhea, and they had not responded to antibiotic treatment. After the fecal microbiota transplantation therapy, the patient's microbiota was followed for a year.
The researchers found out that the patient's intestinal microbiota highly resembled the donor's microbiota and this composition remained stable through-out the one-year follow-up period.
"Our results suggest that intestinal microbiota can be modified relatively permanently. This opens new possibilities to the use this treatment for other diseases related to microbial dysbiosis," says Academy Research Fellow Reetta Satokari from the University of Helsinki.
The researchers also wanted to find out which bacteria among the diverse microbial community are the key species behind the treatment success. In order to understand this, they investigated which bacteria were commonly transferred from the donors to all of the patients. In the future, the promising bacterial species will be isolated and characterized for the design of bacteriotherapy products.
"The aim is to develop a so-called bacterial cocktail that could be used to treat patients instead of the fecal material," the post-doctoral researcher Jonna Jalanka outlines.
Reetta Satokari's group has an interesting ongoing project where they look at the effects of fecal microbiota transplant on antibiotic resistance genes detected in the patient's microbiota. The group just published a study where they showed that the transplant decreases the amount of antibiotic resistant genes found in the patient´s intestinal microbiota. "This is a very important finding because resistance to antibiotics is a big problem and resistant bacterial strains are often found in the intestine," says Satokari.
Fecal microbiota transplantation is an established treatment method for severe antibiotic associated diarrhea where medical treatment has not cleared the infection. It has a high success rate, where over 90 percent of the patients are cured.
"We treat patients with this method in all university hospitals and most of the central hospitals in Finland," tells chief physician Perttu Arkkila from the Helsinki University Hospital endoscopy unit. "Currently, we have ongoing clinical trials where we are investigating the effect of fecal microbiota transplantation in treating irritable bowel syndrome and inflammatory bowel disease."
Arkkila also told that the patients are very eager to enroll the trials since they have often suffered from their condition for a long time and have not found a relief.
The prospective donors are selected carefully. They should be in good general health, normal weight and not have had any antibiotics for the past half a year. Also all donors are tested carefully to exclude several diseases.
Reetta Satokari's group and the hospital clinicians have in collaboration created a unique "fecal bank" where the tested transplants are kept. "Our international colleagues have said to be jealous of this," laughs Satokari. "We aim to share our well received method of regular donors and frozen transplants to other Finnish hospitals. I have just received a grant for this purpose from the Key Project Funding by the Academy of Finland."
Source: University of Helsinki
Redefining Competency: A Comprehensive Framework for Infection Preventionists
December 19th 2024Explore APIC’s groundbreaking framework for defining and documenting infection preventionist competency. Christine Zirges, DNP, ACNS-BC, CIC, FAPIC, shares insights on advancing professional growth, improving patient safety, and navigating regulatory challenges.
Addressing Post-COVID Challenges: The Urgent Need for Enhanced Hospital Reporting Metrics
December 18th 2024Explore why CMS must expand COVID-19, influenza, and RSV reporting to include hospital-onset infections, health care worker cases, and ER trends, driving proactive prevention and patient safety.
Announcing the 2024 Infection Control Today Educator of the Year: Shahbaz Salehi, MD, MPH, MSHIA
December 17th 2024Shahbaz Salehi, MD, MPH, MSHIA, is the Infection Control Today 2024 Educator of the Year. He is celebrated for his leadership, mentorship, and transformative contributions to infection prevention education and patient safety.
Pula General Hospital Celebrates Clean Hospitals
December 16th 2024Learn how Pula General Hospital in Croatia championed infection prevention and environmental hygiene and celebrated Clean Hospitals Day to honor cleaning staff and promote advanced practices for exceptional patient care and safety.
Understanding NHSN's 2022 Rebaseline Data: Key Updates and Implications for HAI Reporting
December 13th 2024Discover how the NHSN 2022 Rebaseline initiative updates health care-associated infection metrics to align with modern health care trends, enabling improved infection prevention strategies and patient safety outcomes.